332 related articles for article (PubMed ID: 23198862)
1. Genetically engineered T cells for the treatment of cancer.
Essand M; Loskog AS
J Intern Med; 2013 Feb; 273(2):166-81. PubMed ID: 23198862
[TBL] [Abstract][Full Text] [Related]
2. Treating cancer with genetically engineered T cells.
Park TS; Rosenberg SA; Morgan RA
Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
[TBL] [Abstract][Full Text] [Related]
3. Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
Ren YB; Sun SJ; Han SY
Curr Pharm Des; 2018; 24(1):78-83. PubMed ID: 29283058
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
5. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
7. Engineered T cells: the promise and challenges of cancer immunotherapy.
Fesnak AD; June CH; Levine BL
Nat Rev Cancer; 2016 Aug; 16(9):566-81. PubMed ID: 27550819
[TBL] [Abstract][Full Text] [Related]
8. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
10. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
11. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
12. [Cellular immunotherapy with genetically engineered T-cell therapy for malignancies].
Fujiwara H
Rinsho Ketsueki; 2011 May; 52(5):243-55. PubMed ID: 21646769
[No Abstract] [Full Text] [Related]
13. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
14. CAR-Ts: new perspectives in cancer therapy.
Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
[TBL] [Abstract][Full Text] [Related]
15. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
Badieyan ZS; Hoseini SS
Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
[TBL] [Abstract][Full Text] [Related]
16. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
17. A novel era of cancer/testis antigen in cancer immunotherapy.
Meng X; Sun X; Liu Z; He Y
Int Immunopharmacol; 2021 Sep; 98():107889. PubMed ID: 34174699
[TBL] [Abstract][Full Text] [Related]
18. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumours with genetically enhanced T lymphocytes.
Sadelain M; Rivière I; Brentjens R
Nat Rev Cancer; 2003 Jan; 3(1):35-45. PubMed ID: 12509765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
